162 related articles for article (PubMed ID: 25764680)
1. [Combined telaprevir plus ribavirin and pegylated interferon therapy for patients with chronic hepatitis C].
Mochida S
Nihon Rinsho; 2015 Feb; 73(2):259-65. PubMed ID: 25764680
[TBL] [Abstract][Full Text] [Related]
2. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
3. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
Ogawa E; Furusyo N; Kajiwara E; Nomura H; Kawano A; Takahashi K; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J
J Gastroenterol Hepatol; 2015 Dec; 30(12):1759-67. PubMed ID: 26095167
[TBL] [Abstract][Full Text] [Related]
5. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
6. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
Burney T; Dusheiko G
Expert Rev Anti Infect Ther; 2011 Feb; 9(2):151-60. PubMed ID: 21143041
[TBL] [Abstract][Full Text] [Related]
7. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
8. Telaprevir for the treatment of chronic hepatitis C infection.
Muir AJ
Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
Ogawa E; Furusyo N; Dohmen K; Kajiwara E; Kawano A; Nomura H; Takahashi K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J;
J Viral Hepat; 2015 Dec; 22(12):992-1001. PubMed ID: 26075320
[TBL] [Abstract][Full Text] [Related]
10. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
[TBL] [Abstract][Full Text] [Related]
11. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
[TBL] [Abstract][Full Text] [Related]
12. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C.
Kanda T; Yokosuka O
JNMA J Nepal Med Assoc; 2011; 51(181):41-8. PubMed ID: 22335095
[TBL] [Abstract][Full Text] [Related]
14. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
15. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
Kumada H; Toyota J; Okanoue T; Chayama K; Tsubouchi H; Hayashi N
J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
[TBL] [Abstract][Full Text] [Related]
16. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P
Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092
[TBL] [Abstract][Full Text] [Related]
17. Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group.
Bai F; Yano Y; Kim SR; Seo Y; Miki A; Saito M; Hirano H; Momose K; Minami A; Hatazawa Y; Hayakumo T; Widasari DI; Rinonce HT; Sugano M; Tani S; Yoon S; Imoto S; Azuma T; Hotta H; Hayashi Y
Int J Mol Med; 2014 Jun; 33(6):1652-6. PubMed ID: 24647743
[TBL] [Abstract][Full Text] [Related]
18. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.
Nehra V; Rizza SA; Talwani R; Temesgen Z
Drugs Today (Barc); 2011 Nov; 47(11):829-37. PubMed ID: 22146226
[TBL] [Abstract][Full Text] [Related]
19. [Triple combination treatment of chronic hepatitis C].
Husa P
Vnitr Lek; 2012; 58(7-8):588-90. PubMed ID: 23067190
[TBL] [Abstract][Full Text] [Related]
20. Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.
Corti G; Salomoni E; Baragli F
Int J Infect Dis; 2014 Feb; 19():85-6. PubMed ID: 24246771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]